Eprenetapopt indicated for the treatment of TP53 Mutant Acute Myeloid Leukemia (AML)... Dec 02
Gritstone Oncology advances into phase 2 expansion cohorts for its personalized neoantigen immunotherapy GRANITE and its off-the-shelf neoantigen immunotherapy SLATE ... Nov 03
Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548 ... Oct 08
The study titled, "The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic," was published this week in the journal Nature.... Aug 05
-Advertisements-